Cyclo (RLsKDK)

Cyclo (RLsKDK) (BK-1361) is a specific inhibitor of metalloproteinase ADAM8 with an IC50 value of 182 nM. cyclo (RLsKDK) has potential applications in inflammatory diseases and cancer[1].

Product Specifications

CAS Number

[1975145-82-4]

Product Name Alternative

BK-1361

UNSPSC

12352209

Target

MMP

Type

Peptides

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cyclo-rlskdk.html

Purity

98.85

Solubility

DMSO : 3.33 mg/mL (ultrasonic)

Smiles

N=C(N)NCCC[C@@H](C(N[C@H](C(N[C@@H](C(N[C@H]1CCCCN)=O)CO)=O)CC(C)C)=O)NC([C@@H](NC([C@@H](NC1=O)CC(O)=O)=O)CCCCN)=O

Molecular Formula

C31H57N11O9

Molecular Weight

727.85

References & Citations

[1]Yim V, et al. Synthesis and biological evaluation of analogues of the potent ADAM8 inhibitor cyclo (RLsKDK) for the treatment of inflammatory diseases and cancer metastasis. Bioorg Med Chem. 2016 Sep 15;24 (18) :4032-4037. |[2]Schlomann U, et al. ADAM8 as a drug target in pancreatic cancer. Nat Commun. 2015 Jan 28;6:6175.